Hims & Hers Health, Inc. (NYSE:HIMS) Shares Bought by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. grew its holdings in Hims & Hers Health, Inc. (NYSE:HIMS) by 15.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,667,422 shares of the company’s stock after purchasing an additional 218,566 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Hims & Hers Health were worth $30,714,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of HIMS. Nisa Investment Advisors LLC raised its stake in Hims & Hers Health by 679.2% during the second quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock worth $37,000 after purchasing an additional 1,603 shares during the period. Quest Partners LLC boosted its holdings in shares of Hims & Hers Health by 5,944.1% in the 2nd quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock valued at $72,000 after buying an additional 3,507 shares during the period. CWM LLC boosted its holdings in shares of Hims & Hers Health by 21.4% in the 3rd quarter. CWM LLC now owns 5,982 shares of the company’s stock valued at $110,000 after buying an additional 1,054 shares during the period. Van ECK Associates Corp bought a new stake in Hims & Hers Health in the 2nd quarter valued at about $111,000. Finally, Amalgamated Bank lifted its position in Hims & Hers Health by 55.9% in the 2nd quarter. Amalgamated Bank now owns 6,566 shares of the company’s stock valued at $133,000 after purchasing an additional 2,354 shares during the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Trading Up 4.5 %

Shares of NYSE HIMS opened at $32.23 on Wednesday. The firm’s 50-day moving average is $22.30 and its 200-day moving average is $20.06. Hims & Hers Health, Inc. has a 1 year low of $8.09 and a 1 year high of $35.02. The firm has a market capitalization of $7.04 billion, a PE ratio of 73.21 and a beta of 1.25.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.26. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The business had revenue of $401.56 million for the quarter, compared to analyst estimates of $382.20 million. During the same quarter last year, the firm earned ($0.04) EPS. Hims & Hers Health’s quarterly revenue was up 77.1% compared to the same quarter last year. As a group, equities research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Insider Buying and Selling at Hims & Hers Health

In related news, insider Michael Chi sold 7,500 shares of the business’s stock in a transaction on Monday, October 21st. The shares were sold at an average price of $22.20, for a total transaction of $166,500.00. Following the transaction, the insider now directly owns 193,980 shares in the company, valued at approximately $4,306,356. The trade was a 3.72 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Soleil Boughton sold 2,339 shares of the business’s stock in a transaction on Tuesday, September 17th. The stock was sold at an average price of $16.50, for a total transaction of $38,593.50. Following the transaction, the insider now owns 176,952 shares in the company, valued at approximately $2,919,708. The trade was a 1.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 974,495 shares of company stock valued at $22,548,139. 17.71% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of analysts have commented on the stock. TD Cowen restated a “buy” rating and set a $28.00 price target on shares of Hims & Hers Health in a research report on Wednesday, November 20th. Piper Sandler reiterated a “neutral” rating and issued a $21.00 target price (up from $18.00) on shares of Hims & Hers Health in a research note on Tuesday, November 5th. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research note on Wednesday, November 6th. Bank of America downgraded shares of Hims & Hers Health from a “buy” rating to an “underperform” rating and reduced their price target for the company from $32.00 to $18.00 in a report on Thursday, November 14th. Finally, Needham & Company LLC began coverage on shares of Hims & Hers Health in a research note on Thursday, August 22nd. They issued a “buy” rating and a $24.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $21.43.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.